Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Breast Neoplasms 71Neoplasm Metastasis 11Brain Neoplasms 7Triple Negative Breast Neoplasms 5Stomach Neoplasms 3Neoplasms 3HER2-positive Breast Cancer 3Colorectal Neoplasms 3Advanced Breast Cancer 3Carcinoma, Non-Small-Cell Lung 2Breast Cancer With Brain Metastasis 2Unresectable Locally Recurrent Breast Cancer 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Meningeal Carcinomatosis 1Inflammatory Breast Neoplasms 1HER2-negative Breast Cancer 1HER2-low Hormone Receptor Positive Breast Cancer 1HER2-Positive Primary Breast Cancer 1HER2 Overexpression 1Glioma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 18Nivolumab 12atezolizumab 5Ipilimumab 4Cyclophosphamide 4fludarabine 3Paclitaxel 3Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3Docetaxel 3Carboplatin 3spartalizumab 2cabozantinib 2avelumab 2aldesleukin 2Specimen Handling 2Interleukin-2 2Immunoglobulin G 2zanidatamab 1veliparib 1trastuzumab deruxtecan 1tislelizumab 1temsirolimus 1sargramostim 1sacituzumab govitecan 1rucaparib 1regorafenib 1poly ICLC 1pemigatinib 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × trastuzumab deruxtecan × Breast × Clear all
NCT03523572 2025-01-27

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Daiichi Sankyo

Phase 1 Completed
86 enrolled 22 charts
BreastGenitourinary

Breast Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡